PPARα-related drugs that might be safe in treating DCM Different from conventional fibrates, pemafibrate (K-877, ParmodiaTM), a novel selective PPARα modulator, is mainly metabolized by the liver [150, 151], and is 2500 times effective in activating PPARα than the conventional fibrates [41, 150] and having a better triglyceride-lowering activity. Here, PPARA is linked to familial dilated cardiomyopathy.